Michael J. Rider, Global General Counsel of ResMed Inc, filed a Form 4 on November 20, 2026, reporting the vesting of performance-based restricted stock units on November 19, 2026, and a related tax-withholding disposition of shares.

Key Highlights

  • Performance RSUs earned: 5,587 shares of ResMed Common Stock were acquired at $0 on November 19, 2026, under transaction code A.
  • Original grant date: The performance-based restricted stock units were originally granted on November 16, 2023.
  • Committee certification: According to the filing, the compensation and leadership development committee certified that performance metrics were met for this portion of the grant.
  • Tax withholding disposal: 3,084 shares were disposed of to the issuer for tax withholding purposes at a price of $236.88 per share on November 19, 2026.
  • Resulting ownership: Following both transactions, Rider directly beneficially owned 12,919 shares of ResMed Common Stock.
  • Reporting person role: Michael J. Rider is identified as Global General Counsel of ResMed Inc (NYSE:RMD).

ResMed General Counsel Rider's November 2026 RSU Vesting Details

According to the Form 4 filed with the SEC on November 20, 2026, Michael J. Rider, Global General Counsel and Secretary of ResMed Inc (NYSE:RMD), reported two transactions in ResMed Common Stock dated November 19, 2026. The first transaction was the acquisition of 5,587 shares at a price of $0, reflecting the earning of performance-based restricted stock units originally granted on November 16, 2023.

The filing states that the shares were earned on November 19, 2026, "when the compensation and leadership development committee certified that the performance metrics were met for this portion of the grant." This acquisition brought Rider's directly held beneficial ownership to 16,004 shares before the subsequent withholding transaction.

The second transaction was a disposition of 3,084 shares to the issuer at $236.88 per share, described in the filing as a "disposition to issuer for tax withholding on vesting of performance-based restricted stock units granted on 11/16/2023." Following both transactions, Rider's direct beneficial ownership stood at 12,919 shares of ResMed Common Stock, as reported in the filing. No derivative securities were reported in Table II of the form.

What Was Disclosed

Michael J. Rider's Form 4 disclosed the earning of 5,587 performance-based RSUs originally granted in November 2023, and the same-day disposal of 3,084 shares for tax withholding at $236.88 each, leaving him with 12,919 directly held shares.